Literature DB >> 7321186

[The absorption, excretion and influence on bowel flora of oral paromomycin sulfate (author's transl)].

S Iwaki, K Honke, N Nishida, N Taniguchi.   

Abstract

The absorption, excretion and influence on bowel flora of oral paromomycin sulfate (aminosidine, PRM) were studied in ten normal volunteers taking a normal diet, and the following results were obtained. 1. Serum levels of PRM were observed 0.46 micrograms/ml at a half hour, 1.14 micrograms/ml at 1 hour, 1.48 micrograms/ml at 2 hours, 0.70 micrograms/ml at 4 hours, 0.29 micrograms at 6 hours and were almost faded out at 12 hours after 4 grams of oral administration. 2. During 0 approximately 2 hours, 2 approximately 4 hours, 4 approximately 6 hours and 6 approximately 12 hours, the mean urine concentration of PRM were observed 56.4 micrograms/ml, 56.2 micrograms/ml, 37.1 micrograms/ml and 13.8 micrograms/ml, respectively, and the total excretion in the urine by 12 hours were observed 21.14 mg (0.53%). 3. Oral administration of PRM caused fall in Lactobacillus, non spore-forming anaerobic Gram positive bacilli (BEP group) and Peptostreptococcus (P less than 0.001), Bacteroides (P less than 0.01). However, after administration was discontinued, reduced bowel flora was returned to the normal range within a few days. No overgrowth of bowel flora by coliform, Clostridium or yeast was observed. Klebsiella oxytoca and toxigenic Clostridium difficile were not observed overgrowth. 4. No side effect was observed clinically over 2 months.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7321186

Source DB:  PubMed          Journal:  Jpn J Antibiot        ISSN: 0368-2781


  3 in total

1.  Paromomycin and geneticin inhibit intracellular Cryptosporidium parvum without trafficking through the host cell cytoplasm: implications for drug delivery.

Authors:  J K Griffiths; R Balakrishnan; G Widmer; S Tzipori
Journal:  Infect Immun       Date:  1998-08       Impact factor: 3.441

2.  Interest in paromomycin for the treatment of visceral leishmaniasis (kala-azar).

Authors:  Viroj Wiwanitkit
Journal:  Ther Clin Risk Manag       Date:  2012-06-22       Impact factor: 2.423

3.  Investigation of in vitro absorption, distribution, metabolism, and excretion and in vivo pharmacokinetics of paromomycin: Influence on oral bioavailability.

Authors:  M Jakir S K Pinjari; Rahul Somani; Ritu M Gilhotra
Journal:  Indian J Pharmacol       Date:  2017 Jul-Aug       Impact factor: 1.200

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.